# Benigno Rodriguez

# List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/2268308/benigno-rodriguez-publications-by-year.pdf

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

12,644 145 51 111 h-index g-index citations papers 148 14,324 7.7 5.35 L-index ext. citations avg, IF ext. papers

#	Paper	IF	Citations
145	CD4 Count at Entry into Care and at Antiretroviral Therapy Prescription among Adults with Human Immunodeficiency Virus in the United States, 2005-2018. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 73, e2334-e	23 <del>37</del> 6	4
144	Current and Past Immunodeficiency Are Associated With Higher Hospitalization Rates Among Persons on Virologically Suppressive Antiretroviral Therapy for up to 11 Years. <i>Journal of Infectious Diseases</i> , <b>2021</b> , 224, 657-666	7	1
143	Hospitalization Rates and Causes Among Persons With HIV in the United States and Canada, 2005-2015. <i>Journal of Infectious Diseases</i> , <b>2021</b> , 223, 2113-2123	7	5
142	Markers of T Cell Exhaustion and Senescence and Their Relationship to Plasma TGF-Levels in Treated HIV+ Immune Non-responders. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 638010	8.4	4
141	Translocated microbiome composition determines immunological outcome in treated HIV infection. <i>Cell</i> , <b>2021</b> , 184, 3899-3914.e16	56.2	8
140	Antiretroviral drug class and anaemia risk in the current treatment era among people living with HIV in the USA: a clinical cohort study. <i>BMJ Open</i> , <b>2020</b> , 10, e031487	3	1
139	Physical activity trends and metabolic health outcomes in people living with HIV in the US, 2008-2015. <i>Progress in Cardiovascular Diseases</i> , <b>2020</b> , 63, 170-177	8.5	6
138	The PROSPER-HIV Study: A Research Protocol to Examine Relationships Among Physical Activity, Diet Intake, and Symptoms in Adults Living With HIV. <i>Journal of the Association of Nurses in AIDS Care</i> , <b>2020</b> , 31, 346-352	1.6	1
137	Inflammescent CX3CR1+CD57+CD8+ T cells are generated and expanded by IL-15. <i>JCI Insight</i> , <b>2020</b> , 5,	9.9	11
136	Substantial decline in heavily treated therapy-experienced persons with HIV with limited antiretroviral treatment options. <i>Aids</i> , <b>2020</b> , 34, 2051-2059	3.5	6
135	Association of Immunosuppression and Human Immunodeficiency Virus (HIV) Viremia With Anal Cancer Risk in Persons Living With HIV in the United States and Canada. <i>Clinical Infectious Diseases</i> , <b>2020</b> , 70, 1176-1185	11.6	14
134	Association of immunosuppression and HIV viraemia with non-Hodgkin lymphoma risk overall and by subtype in people living with HIV in Canada and the USA: a multicentre cohort study. <i>Lancet HIV,the</i> , <b>2019</b> , 6, e240-e249	7.8	25
133	Effectiveness of Direct-Acting Antiviral Therapy in Patients With Human Immunodeficiency Virus-Hepatitis C Virus Coinfection in Routine Clinical Care: A Multicenter Study. <i>Open Forum Infectious Diseases</i> , <b>2019</b> , 6, ofz100	1	12
132	Stability of plasma indices of inflammation/coagulation and homeostasis after fatty and non-fatty meals in treated people with HIV. <i>Journal of Virus Eradication</i> , <b>2019</b> , 5, 28-32	2.8	
131	Virologic Failure Among People Living With HIV Initiating Dolutegravir-Based Versus Other Recommended Regimens in Real-World Clinical Care Settings. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2019</b> , 81, 572-577	3.1	9
130	One Size Fits (n)One: The Influence of Sex, Age, and Sexual Human Immunodeficiency Virus (HIV) Acquisition Risk on Racial/Ethnic Disparities in the HIV Care Continuum in the United States. <i>Clinical Infectious Diseases</i> , <b>2019</b> , 68, 795-802	11.6	9
129	Physical Activity Intensity is Associated with Symptom Distress in the CNICS Cohort. <i>AIDS and Behavior</i> , <b>2019</b> , 23, 627-635	4.3	14

## (2016-2018)

128	Multimorbidity Among Persons Living with Human Immunodeficiency Virus in the United States. <i>Clinical Infectious Diseases</i> , <b>2018</b> , 66, 1230-1238	11.6	83
127	Pre-vaccine plasma levels of soluble inflammatory indices negatively predict responses to HAV, HBV, and tetanus vaccines in HCV and HIV infection. <i>Vaccine</i> , <b>2018</b> , 36, 453-460	4.1	12
126	Changes in Inflammation but Not in T-Cell Activation Precede Non-AIDS-Defining Events in a Case-Control Study of Patients on Long-term Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , <b>2018</b> , 218, 239-248	7	18
125	Influence of Substance Use Disorders on 2-Year HIV Care Retention in the United States. <i>AIDS and Behavior</i> , <b>2018</b> , 22, 742-751	4.3	21
124	Differentiation of Type 1 and Type 2 Myocardial Infarctions Among HIV-Infected Patients Requires Adjudication Due to Overlap in Risk Factors. <i>AIDS Research and Human Retroviruses</i> , <b>2018</b> , 34, 916-921	1.6	0
123	HIV Viral Suppression Trends Over Time Among HIV-Infected Patients Receiving Care in the United States, 1997 to 2015: A Cohort Study. <i>Annals of Internal Medicine</i> , <b>2018</b> , 169, 376-384	8	67
122	Cycling CD4+ T cells in HIV-infected immune nonresponders have mitochondrial dysfunction. Journal of Clinical Investigation, <b>2018</b> , 128, 5083-5094	15.9	35
121	Lymphoid tissue fibrosis is associated with impaired vaccine responses. <i>Journal of Clinical Investigation</i> , <b>2018</b> , 128, 2763-2773	15.9	33
120	Identifying HIV care enrollees at-risk for cannabis use disorder. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , <b>2017</b> , 29, 846-850	2.2	11
119	Comparison of Kaposi Sarcoma Risk in Human Immunodeficiency Virus-Positive Adults Across 5 Continents: A Multiregional Multicohort Study. <i>Clinical Infectious Diseases</i> , <b>2017</b> , 65, 1316-1326	11.6	23
118	Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial. <i>PLoS Medicine</i> , <b>2017</b> , 14, e1002435	11.6	71
117	Cancer-Attributable Mortality Among People With Treated Human Immunodeficiency Virus Infection in North America. <i>Clinical Infectious Diseases</i> , <b>2017</b> , 65, 636-643	11.6	44
116	Impaired human immunodeficiency virus type 1 replicative fitness in atypical viremic non-progressor individuals. <i>AIDS Research and Therapy</i> , <b>2017</b> , 14, 15	3	6
115	Prevalence and Predictors of Substance Use Disorders Among HIV Care Enrollees in the United States. <i>AIDS and Behavior</i> , <b>2017</b> , 21, 1138-1148	4.3	87
114	Immunologic Effects of Maraviroc in HIV-Infected Patients with Severe CD4 Lymphopenia Starting Antiretroviral Therapy: A Sub-Study of the CADIRIS Trial. <i>Pathogens and Immunity</i> , <b>2017</b> , 2, 151-177	4.9	2
113	Prospective Analysis of Lipid Composition Changes with Antiretroviral Therapy and Immune Activation in Persons Living with HIV. <i>Pathogens and Immunity</i> , <b>2017</b> , 2, 376-403	4.9	19
112	CD8 T-Cell Expansion and Inflammation Linked to CMV Coinfection in ART-treated HIV Infection. <i>Clinical Infectious Diseases</i> , <b>2016</b> , 62, 392-6	11.6	84
111	During Hepatitis C Virus (HCV) Infection and HCV-HIV Coinfection, an Elevated Plasma Level of Autotaxin Is Associated With Lysophosphatidic Acid and Markers of Immune Activation That Normalize During Interferon-Free HCV Therapy. <i>Journal of Infectious Diseases</i> , <b>2016</b> , 214, 1438-1448	7	25

110	Inflammation Perturbs the IL-7 Axis, Promoting Senescence and Exhaustion that Broadly Characterize Immune Failure in Treated HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), <b>2016</b> , 71, 483-92	3.1	35
109	Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy. <i>International Journal of Epidemiology</i> , <b>2016</b> , 45, 2038-2049	7.8	24
108	IL-15 promotes activation and expansion of CD8+ T cells in HIV-1 infection. <i>Journal of Clinical Investigation</i> , <b>2016</b> , 126, 2745-56	15.9	57
107	Poorly Controlled HIV Infection: An Independent Risk Factor for Liver Fibrosis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2016</b> , 72, 437-43	3.1	32
106	End-stage renal disease among HIV-infected adults in North America. <i>Clinical Infectious Diseases</i> , <b>2015</b> , 60, 941-9	11.6	112
105	Oxidized LDL Levels Are Increased in HIV Infection and May Drive Monocyte Activation. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2015</b> , 69, 154-60	3.1	65
104	Natural cytotoxicity receptor-dependent natural killer cytolytic activity directed at hepatitis C Virus (HCV) is associated with liver inflammation, African American race, IL28B genotype, and response to pegylated interferon/ribavirin therapy in chronic HCV infection. <i>Journal of Infectious Diseases</i> ,	7	8
103	A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of a Chemokine Receptor 5 (CCR5) Antagonist to Decrease the Occurrence of Immune Reconstitution Inflammatory Syndrome in HIV-Infection: The CADIRIS Study. <i>Lancet HIV,the</i> , <b>2014</b> , 1, e60-e67	7.8	41
102	Identification of occult Fusobacterium nucleatum central nervous system infection by use of PCR-electrospray ionization mass spectrometry. <i>Journal of Clinical Microbiology</i> , <b>2014</b> , 52, 3462-4	9.7	6
101	Inflammatory cytokines drive CD4+ T-cell cycling and impaired responsiveness to interleukin 7: implications for immune failure in HIV disease. <i>Journal of Infectious Diseases</i> , <b>2014</b> , 210, 619-29	7	62
100	Lymphoma immune reconstitution inflammatory syndrome in the center for AIDS research network of integrated clinical systems cohort. <i>Clinical Infectious Diseases</i> , <b>2014</b> , 59, 279-86	11.6	30
99	Factors associated with delayed hepatitis B viral suppression on tenofovir among patients coinfected with HBV-HIV in the CNICS cohort. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), <b>2014</b> , 66, 96-101	3.1	21
98	African ancestry influences CCR5 -2459G>A genotype-associated virologic success of highly active antiretroviral therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2014</b> , 66, 102-7	3.1	5
97	Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection. <i>Journal of Infectious Diseases</i> , <b>2014</b> , 210, 1228-38	7	317
96	HIV viremia and incidence of non-Hodgkin lymphoma in patients successfully treated with antiretroviral therapy. <i>Clinical Infectious Diseases</i> , <b>2014</b> , 58, 1599-606	11.6	34
95	Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. <i>Journal of Infectious Diseases</i> , <b>2014</b> , 210, 1248-59	7	351
94	Current practices of screening for incident hepatitis C virus (HCV) infection among HIV-infected, HCV-uninfected individuals in primary care. <i>Clinical Infectious Diseases</i> , <b>2014</b> , 59, 1686-93	11.6	16
93	Incidence and timing of cancer in HIV-infected individuals following initiation of combination antiretroviral therapy. <i>Clinical Infectious Diseases</i> , <b>2013</b> , 57, 756-64	11.6	85

### (2012-2013)

92	Hepatitis C viremia and the risk of chronic kidney disease in HIV-infected individuals. <i>Journal of Infectious Diseases</i> , <b>2013</b> , 208, 1240-9	7	39
91	Trends and disparities in antiretroviral therapy initiation and virologic suppression among newly treatment-eligible HIV-infected individuals in North America, 2001-2009. <i>Clinical Infectious Diseases</i> , <b>2013</b> , 56, 1174-82	11.6	82
90	The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial. <i>Blood</i> , <b>2013</b> , 121, 4635-46	2.2	113
89	Temporal trends in presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era. <i>Journal of the National Cancer Institute</i> , <b>2013</b> , 105, 1221-9	9.7	111
88	Impaired T-cell responses to sphingosine-1-phosphate in HIV-1 infected lymph nodes. <i>Blood</i> , <b>2013</b> , 121, 2914-22	2.2	29
87	Association of early HIV viremia with mortality after HIV-associated lymphoma. <i>Aids</i> , <b>2013</b> , 27, 2365-73	3.5	29
86	Plasma proteome analysis reveals overlapping, yet distinct mechanisms of immune activation in chronic HCV and HIV infections. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2013</b> , 63, 563-	プ1 <sup>1</sup>	15
85	Predictive accuracy of the Veterans Aging Cohort Study index for mortality with HIV infection: a North American cross cohort analysis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2013</b> , 62, 149-63	3.1	156
84	Treatment failure and drug resistance is more frequent in HIV-1 subtype D versus subtype A-infected Ugandans over a 10-year study period. <i>Aids</i> , <b>2013</b> , 27, 1899-909	3.5	27
83	Safety, tolerability, and immunogenicity of repeated doses of dermavir, a candidate therapeutic HIV vaccine, in HIV-infected patients receiving combination antiretroviral therapy: results of the ACTG 5176 trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2013</b> , 64, 351-9	3.1	46
82	High levels of antiretroviral use and viral suppression among persons in HIV care in the United States, 2010. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2013</b> , 63, 299-306	3.1	47
81	Interferon-ls the primary plasma type-I IFN in HIV-1 infection and correlates with immune activation and disease markers. <i>PLoS ONE</i> , <b>2013</b> , 8, e56527	3.7	114
80	Association between U.S. state AIDS Drug Assistance Program (ADAP) features and HIV antiretroviral therapy initiation, 2001-2009. <i>PLoS ONE</i> , <b>2013</b> , 8, e78952	3.7	9
79	Effect of Nadir CD4+ T cell count on clinical measures of periodontal disease in HIV+ adults before and during immune reconstitution on HAART. <i>PLoS ONE</i> , <b>2013</b> , 8, e76986	3.7	8
78	Dynamics of immune reconstitution and activation markers in HIV+ treatment-nalle patients treated with raltegravir, tenofovir disoproxil fumarate and emtricitabine. <i>PLoS ONE</i> , <b>2013</b> , 8, e83514	3.7	41
77	Genetic variations in loci relevant to natural killer cell function are affected by ethnicity but are generally not correlated with susceptibility to HIV-1. <i>Tissue Antigens</i> , <b>2012</b> , 79, 367-71		7
76	Shared monocyte subset phenotypes in HIV-1 infection and in uninfected subjects with acute coronary syndrome. <i>Blood</i> , <b>2012</b> , 120, 4599-608	2.2	155
75	Can immune-related genotypes illuminate the immunopathogenesis of cytomegalovirus disease in human immunodeficiency virus-infected patients?. <i>Human Immunology</i> , <b>2012</b> , 73, 168-74	2.3	4

74	Dissecting the T Cell Response: Proliferation Assays vs. Cytokine Signatures by ELISPOT. <i>Cells</i> , <b>2012</b> , 1, 127-40	7.9	15
73	HIV pathogenesis: the host. <i>Cold Spring Harbor Perspectives in Medicine</i> , <b>2012</b> , 2, a007005	5.4	55
72	Baseline levels of soluble CD14 and CD16+56- natural killer cells are negatively associated with response to interferon/ribavirin therapy during HCV-HIV-1 coinfection. <i>Journal of Infectious Diseases</i> , <b>2012</b> , 206, 969-73	7	15
71	Characterizing HIV transmission networks across the United States. <i>Clinical Infectious Diseases</i> , <b>2012</b> , 55, 1135-43	11.6	98
70	Disseminated Mycobacterium chelonae infection in a patient receiving an epidermal growth factor receptor inhibitor for advanced head and neck cancer. <i>Journal of Clinical Microbiology</i> , <b>2012</b> , 50, 194-5	9.7	9
69	Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: results of a phase I/IIa randomized, placebo-controlled, multicenter study. <i>Clinical Infectious Diseases</i> , <b>2012</b> , 55, 291-300	11.6	174
68	Bacterial colonization and beta defensins in the female genital tract in HIV infection. <i>Current HIV Research</i> , <b>2012</b> , 10, 504-12	1.3	10
67	Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. <i>Clinical Infectious Diseases</i> , <b>2012</b> , 54, 1026-34	11.6	383
66	Genetically associated CD16(+)56(-) natural killer cell interferon (IFN)- <b>R</b> expression regulates signaling and is implicated in IFN-⊞nduced hepatitis C virus decline. <i>Journal of Infectious Diseases</i> , <b>2012</b> , 205, 1131-41	7	8
65	Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care. <i>Aids</i> , <b>2012</b> , 26, 1907-15	3.5	93
64	Increased platelet and microparticle activation in HIV infection: upregulation of P-selectin and tissue factor expression. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2012</b> , 59, 340-6	3.1	108
63	HIV-1 is not a major driver of increased plasma IL-6 levels in chronic HIV-1 disease. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2012</b> , 61, 145-52	3.1	26
62	Interferon-alpha administration enhances CD8+ T cell activation in HIV infection. <i>PLoS ONE</i> , <b>2012</b> , 7, e3	03,96	37
61	Transmitted drug resistance in the CFAR network of integrated clinical systems cohort: prevalence and effects on pre-therapy CD4 and viral load. <i>PLoS ONE</i> , <b>2011</b> , 6, e21189	3.7	28
60	Systemic immune activation in HIV infection is associated with decreased MDC responsiveness to TLR ligand and inability to activate naive CD4 T-cells. <i>PLoS ONE</i> , <b>2011</b> , 6, e23884	3.7	22
59	Impact of NRTIs on lipid levels among a large HIV-infected cohort initiating antiretroviral therapy in clinical care. <i>Aids</i> , <b>2011</b> , 25, 185-95	3.5	64
58	Frequencies of FoxP3+ naive T cells are related to both viral load and naive T cell proliferation responses in HIV disease. <i>Journal of Leukocyte Biology</i> , <b>2011</b> , 90, 621-8	6.5	3
57	A prospective cohort study of periodontal disease measures and cardiovascular disease markers in HIV-infected adults. <i>AIDS Research and Human Retroviruses</i> , <b>2011</b> , 27, 1157-66	1.6	14

#### (2009-2011)

56	Novel method for simultaneous quantification of phenotypic resistance to maturation, protease, reverse transcriptase, and integrase HIV inhibitors based on 3RGag(p2/p7/p1/p6)/PR/RT/INT-recombinant viruses: a useful tool in the multitarget era of	5.9	19
55	Reduced naive CD4 T cell numbers and impaired induction of CD27 in response to T cell receptor stimulation reflect a state of immune activation in chronic hepatitis C virus infection. <i>Journal of Infectious Diseases</i> , <b>2011</b> , 203, 635-45	7	43
54	Missing data on the estimation of the prevalence of accumulated human immunodeficiency virus drug resistance in patients treated with antiretroviral drugs in north america. <i>American Journal of Epidemiology</i> , <b>2011</b> , 174, 727-35	3.8	9
53	Chemokine (C-C motif) receptor 5 -2459 genotype in patients receiving highly active antiretroviral therapy: race-specific influence on virologic success. <i>Journal of Infectious Diseases</i> , <b>2011</b> , 204, 291-8	7	10
52	Risk factors for tuberculosis after highly active antiretroviral therapy initiation in the United States and Canada: implications for tuberculosis screening. <i>Journal of Infectious Diseases</i> , <b>2011</b> , 204, 893-901	7	31
51	Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells. <i>Journal of Infectious Diseases</i> , <b>2011</b> , 204, 1217-26	7	228
50	Determinants of protection among HIV-exposed seronegative persons: an overview. <i>Journal of Infectious Diseases</i> , <b>2010</b> , 202 Suppl 3, S333-8	7	47
49	Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy. <i>Journal of Infectious Diseases</i> , <b>2010</b> , 201, 1796-805	7	107
48	Peripheral blood B cell subset skewing is associated with altered cell cycling and intrinsic resistance to apoptosis and reflects a state of immune activation in chronic hepatitis C virus infection. <i>Journal of Immunology</i> , <b>2010</b> , 185, 3019-27	5.3	47
47	Late presentation for human immunodeficiency virus care in the United States and Canada. <i>Clinical Infectious Diseases</i> , <b>2010</b> , 50, 1512-20	11.6	165
46	Perforin expression directly ex vivo by HIV-specific CD8 T-cells is a correlate of HIV elite control. <i>PLoS Pathogens</i> , <b>2010</b> , 6, e1000917	7.6	246
45	Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activation. <i>Blood</i> , <b>2010</b> , 115, 161-7	2.2	195
44	In vitro naWe T cell proliferation failure predicts poor post-immunization responses to neoantigen, but not recall antigens, in HIV-infection. <i>Clinical Immunology</i> , <b>2010</b> , 136, 400-8	9	6
43	Comparative description of haplotype structure and genetic diversity of MDR1 (ABCB1) in HIV-positive and HIV-negative populations. <i>Infection, Genetics and Evolution</i> , <b>2010</b> , 10, 60-7	4.5	5
42	CD4 count at presentation for HIV care in the United States and Canada: are those over 50 years more likely to have a delayed presentation?. <i>AIDS Research and Therapy</i> , <b>2010</b> , 7, 45	3	63
41	Differential effects of hepatitis C virus JFH1 on human myeloid and plasmacytoid dendritic cells. <i>Journal of Virology</i> , <b>2009</b> , 83, 5693-707	6.6	28
40	Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. <i>Journal of Infectious Diseases</i> , <b>2009</b> , 199, 1177-85	7	465
39	Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. <i>Clinical Infectious Diseases</i> , <b>2009</b> , 48, 787-94	11.6	281

38	Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. <i>Aids</i> , <b>2009</b> , 23, 1359-66	3.5	254
37	Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384. <i>Clinical Infectious Diseases</i> , <b>2009</b> , 48, 350-61	11.6	180
36	Impaired plasmacytoid dendritic cell (PDC)-NK cell activity in viremic human immunodeficiency virus infection attributable to impairments in both PDC and NK cell function. <i>Journal of Virology</i> , <b>2009</b> , 83, 11175-87	6.6	35
35	Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. <i>Clinical Infectious Diseases</i> , <b>2009</b> , 49, 1582-90	11.6	51
34	Accessory cell dependent NK cell mediated PBMC IFN-gamma production is defective in HIV infection. <i>Clinical Immunology</i> , <b>2009</b> , 131, 288-97	9	9
33	Effect of early versus deferred antiretroviral therapy for HIV on survival. <i>New England Journal of Medicine</i> , <b>2009</b> , 360, 1815-26	59.2	852
32	S03-06 OA. Rapid perforin upregulation by CD8 T cells in elite controllers as a correlate of immune-mediated control of HIV replication. <i>Retrovirology</i> , <b>2009</b> , 6,	3.6	78
31	Desensitization to type I interferon in HIV-1 infection correlates with markers of immune activation and disease progression. <i>Blood</i> , <b>2009</b> , 113, 5497-505	2.2	40
30	Impaired naive and memory B-cell responsiveness to TLR9 stimulation in human immunodeficiency virus infection. <i>Journal of Virology</i> , <b>2008</b> , 82, 7837-45	6.6	34
29	Hepatitis C virus-specific T-cell gamma interferon and proliferative responses are more common in perihepatic lymph nodes than in peripheral blood or liver. <i>Journal of Virology</i> , <b>2008</b> , 82, 11742-8	6.6	7
28	Randomized study of dual versus single ritonavir-enhanced protease inhibitors for protease inhibitor-experienced patients with HIV. <i>HIV Clinical Trials</i> , <b>2008</b> , 9, 91-102		10
27	Cohort profile: the Centers for AIDS Research Network of Integrated Clinical Systems. <i>International Journal of Epidemiology</i> , <b>2008</b> , 37, 948-55	7.8	193
26	Increased levels of human beta-defensins mRNA in sexually HIV-1 exposed but uninfected individuals. <i>Current HIV Research</i> , <b>2008</b> , 6, 531-8	1.3	67
25	Toll-like receptor ligands induce human T cell activation and death, a model for HIV pathogenesis. <i>PLoS ONE</i> , <b>2008</b> , 3, e1915	3.7	109
24	TLR9 stimulation drives nalle B cells to proliferate and to attain enhanced antigen presenting function. <i>European Journal of Immunology</i> , <b>2007</b> , 37, 2205-13	6.1	115
23	HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. <i>Clinical Infectious Diseases</i> , <b>2007</b> , 44, 591-5	11.6	154
22	Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). <i>International Journal of Epidemiology</i> , <b>2007</b> , 36, 294-301	7.8	139
21	Presenting Plasma HIV RNA Level and Rate of CD4 T-Cell DeclineReply. <i>JAMA - Journal of the American Medical Association</i> , <b>2007</b> , 297, 805	27.4	

20	Statins Blunt HAART-Induced CD4 T-Cell Gains but Have No Long-Term Effect on Virologic Response to HAART. <i>Journal of the International Association of Providers of AIDS Care</i> , <b>2007</b> , 6, 198-202		12
19	Abnormal activation and cytokine spectra in lymph nodes of people chronically infected with HIV-1. <i>Blood</i> , <b>2007</b> , 109, 4272-9	2.2	166
18	Monitoring clinical trials of therapeutic vaccines in HIV infection: role of treatment interruption. <i>Current Opinion in HIV and AIDS</i> , <b>2007</b> , 2, 56-61	4.2	8
17	TLR ligand-dependent activation of naive CD4 T cells by plasmacytoid dendritic cells is impaired in hepatitis C virus infection. <i>Journal of Immunology</i> , <b>2007</b> , 178, 4436-44	5.3	64
16	Interferon-alpha differentially rescues CD4 and CD8 T cells from apoptosis in HIV infection. <i>Aids</i> , <b>2006</b> , 20, 1379-89	3.5	31
15	Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2006</b> , 42, 426-34	3.1	134
14	Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. JAMA - Journal of the American Medical Association, 2006, 296, 1498-506	27.4	241
13	Cyclosporin A provides no sustained immunologic benefit to persons with chronic HIV-1 infection starting suppressive antiretroviral therapy: results of a randomized, controlled trial of the AIDS Clinical Trials Group A5138. <i>Journal of Infectious Diseases</i> , <b>2006</b> , 194, 1677-85	7	34
12	HIV coinfection impairs CD28-mediated costimulation of hepatitis C virus-specific CD8 cells. <i>Journal of Infectious Diseases</i> , <b>2006</b> , 194, 391-400	7	14
11	Gender differences in human immunodeficiency virus (HIV) RNA and CD4 cell counts among new entrants to HIV care. <i>Clinical Microbiology and Infection</i> , <b>2006</b> , 12, 389-91	9.5	8
10	Microbial translocation is a cause of systemic immune activation in chronic HIV infection. <i>Nature Medicine</i> , <b>2006</b> , 12, 1365-71	50.5	2632
9	Persistent replication of human immunodeficiency virus type 1 despite treatment of pulmonary tuberculosis in dually infected subjects. <i>Vaccine Journal</i> , <b>2005</b> , 12, 1298-304		19
8	New entrants to HIV care are presenting only at marginally earlier stages of disease but may increasingly represent groups perceived at lower risk. <i>Journal of the International Association of Providers of AIDS Care</i> , <b>2005</b> , 4, 47-51		2
7	Impaired monocyte maturation in response to CpG oligodeoxynucleotide is related to viral RNA levels in human immunodeficiency virus disease and is at least partially mediated by deficiencies in alpha/beta interferon responsiveness and production. <i>Journal of Virology</i> , <b>2005</b> , 79, 4109-19	6.6	34
6	Peripheral S-phase T cells in HIV disease have a central memory phenotype and rarely have evidence of recent T cell receptor engagement. <i>Journal of Infectious Diseases</i> , <b>2005</b> , 192, 62-70	7	37
5	Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. <i>Science</i> , <b>2004</b> , 306, 485-7	33.3	329
4	Effect of GB virus C coinfection on response to antiretroviral treatment in human immunodeficiency virus-infected patients. <i>Journal of Infectious Diseases</i> , <b>2003</b> , 187, 504-7	7	34
3	Plasma levels of B-lymphocyte stimulator increase with HIV disease progression. <i>Aids</i> , <b>2003</b> , 17, 1983-5	3.5	42

Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. *Aids*, **2003**, 17, 1907-15

3.5 197

A family cluster of five cases of group A streptococcal pneumonia. *Pediatrics*, **2003**, 112, e61-5

7.4 18